Metastatic Breast Carcinoma clinical trials in Florida

Personalized Neoantigen Peptide-Based Vaccine in Combination With Pembrolizumab for Treatment of Advanced Solid Tumors

Testing a new drug for breast cancer and other solid tumors

This trial tests a new oral drug (BGB-43395) alone or with other treatments for people with advanced breast cancer or other solid tumors that depend on CDK4. It aims to find safe doses and see if the drug helps shrink tumors or slow growth.

Palazestrant and ribociclib for first-line advanced breast cancer

This trial tests a new drug (palazestrant) combined with ribociclib for people with a common type of advanced breast cancer that is estrogen receptor-positive and HER2-negative. You may qualify if you haven't had treatment for advanced disease and your cancer has either just been found or came back long after completing hormone therapy.

Datopotamab deruxtecan for breast cancer with brain spread

This trial tests a new drug called datopotamab deruxtecan for people with HER2-negative breast cancer that has spread to the brain. It looks at how well the drug works against brain metastases.

Find targeted cancer treatments using genetic testing

This study matches people with advanced solid tumors to targeted treatment plans based on genetic testing. It also requires tumor sample testing to help doctors choose the most promising therapy for your specific tumor changes.

Vaccine plus pembrolizumab for breast cancer in the brain

This trial studies whether a personalized immune-cell vaccine (dendritic cell vaccine) combined with pembrolizumab can help control brain metastases from certain types of breast cancer. It may help your immune system better recognize and attack cancer cells in the brain.

Testing a new combination treatment for advanced breast cancer

This study tests two experimental drugs, BNT323 and BNT327, together in people with advanced breast cancer. The goal is to find the best dose and see if the combination is safe and helpful.

Individualized vaccine added to standard treatment for metastatic triple-negative breast cancer

This Phase 2 trial tests whether adding a personalized cancer vaccine to durvalumab (an immunotherapy), tremelimumab (another immunotherapy), and chemotherapy can improve outcomes for people with metastatic triple-negative breast cancer. It may help your immune system recognize your specific tumor features.

Imaging small live tumor details during surgery

This study uses a special camera to look at solid tumors from inside the body during an operation. It tests whether “live” tumor imaging (using a medicine called fluorescein) can be safely performed in people with certain solid cancers.

Tumor-pulse device for spinal cancer fluid spread

This trial tests whether Tumor Treating Fields (a non-surgical device that delivers treatment signals to cancer cells through the scalp/skin) can help people whose breast or lung cancer has spread into the fluid around the spine and brain. It focuses on people who have cancer cells found in spinal fluid and can safely use the device most of the day.

Early cancer drug study for adults with advanced tumors

This Phase 1 study tests early (first-in-program) cancer medicines in people whose cancer has not been adequately controlled. It helps researchers learn the safest dose and early signs of whether the treatment may work for different tumor types and treatments.

Bria-IMT plus CPI vs standard care for advanced breast cancer

This trial tests a new combination of two immunotherapy drugs (Bria-IMT and a checkpoint inhibitor) against your doctor's choice of standard treatments. It is for people with advanced breast cancer that has spread and who have already tried several prior therapies.

Testing a live tumor test for immune therapy response

This trial uses a special test on live tumor samples to see if it can predict how well immune checkpoint inhibitors (a type of immunotherapy) will work for different cancers. It may help doctors choose the best treatment for you.

Blood test study for HR+ breast cancer treatment monitoring

This study looks at a blood test (DiviTum TKa) to see how well it measures treatment response in people with hormone receptor-positive (HR+) breast cancer that has spread. The test may help doctors know if a treatment is working.

Standard vs longer radiation for brain metastases

This trial compares the usual short course of radiation therapy (one session) to a longer course (up to 5 sessions) for people with cancer that has spread to the brain. The goal is to see if the longer course works better and causes fewer side effects.

Proton vs standard radiation for cancer spread to brain/spine lining

This trial compares a newer type of radiation (proton therapy) to standard radiation for people whose breast or lung cancer has spread to the lining of the brain and spinal cord. It aims to see if proton therapy can better control the disease while causing fewer side effects.

Study of NKT3964 for advanced solid tumors

This trial is testing an experimental oral drug called NKT3964 for people with advanced solid tumors that have stopped responding to standard treatments. The drug works by blocking a protein called CDK2, which some cancers need to grow.

Testing skipping breast surgery or radiation for top responders

This trial studies whether some people with early-stage breast cancer who respond extremely well to hormone/chemo/targeted treatment can safely skip breast surgery and/or radiation. It aims to reduce side effects without increasing cancer risk in carefully selected patients.

Study of heart-risk management for metastatic HER2 breast cancer

This trial follows people with metastatic HER2-positive breast cancer who are at higher risk for heart damage while on HER2-targeted therapy. Some participants are randomly assigned to different monitoring/heart-protection approaches to see what best helps keep the heart safe.

RLY-2608 for PIK3CA-mutant advanced solid tumors and breast cancer

This early study (Phase 1) tests RLY-2608, a targeted cancer drug for tumors with a PIK3CA mutation. It studies the drug alone and combined with hormone therapy (and sometimes CDK4/6 or CDK4 medicines) to see safety, dose, and whether it can shrink tumors.

Adding immunotherapy to chemo for stage II-III breast cancer

This trial tests whether adding the immunotherapy drug durvalumab to standard chemotherapy works better than chemo alone for people with hormone receptor positive, HER2 negative breast cancer that is stage II or III and has a high-risk genetic score (MammaPrint High Risk 2).

SBRT radiation plus standard treatment for spread cancer

This trial looks at adding a focused radiation treatment called SBRT to standard care for cancers that have spread to a limited number of spots. It aims to control those spread-out tumors while still using the usual cancer treatment plan.

Trastuzumab deruxtecan with or without anastrozole for early breast cancer

This Phase 2 study tests whether trastuzumab deruxtecan alone or combined with anastrozole can control early-stage breast cancer that is HER2-low and hormone-receptor positive. It aims to improve outcomes after initial surgical treatment by targeting cancer cells that may have low levels of HER2.

INX-315 for advanced cancers with a specific gene change

This trial studies an experimental medicine (INX-315) given in an “open-label” way to people with advanced cancer that has not responded to prior treatment. It mainly looks at safety and side effects first, and also checks how well it works in cancers with a specific gene amplification.